What is Avail Pharma?
Avail Pharma operates as the dedicated consulting division of AVAIL, established in June 1998. The firm is distinguished by its team of highly-qualified consultants, possessing proven analytical and problem-solving acumen, coupled with deep knowledge in strategic pharmaceutical and biotechnological fields. Specialists in drug development, regulatory affairs, and international medical marketing bring over a decade of industry experience from key decision-making roles. Avail Pharma leverages an extensive international and multidisciplinary network of external experts, including board-certified medical specialists, pharmaceutical physicians across various therapeutic areas, modeling and simulation experts, pharmacogenomic data specialists, statisticians, former health authority officers, and skilled regulatory and medical writers. This robust network allows the company to provide comprehensive, on-demand support for complex challenges in the life sciences sector.
How much funding has Avail Pharma raised?
Avail Pharma has raised a total of $7.1M across 4 funding rounds:
Debt
$125K
Angel/Seed
$750K
Other Financing Round
$2M
Series A
$4.2M
Debt (2013): $125K, investors not publicly disclosed
Angel/Seed (2015): $750K led by Steve Olechowski and Metaprop
Other Financing Round (2017): $2M supported by M25 Group, Charmides Capital, Sandalphon Capital,, and Cultivation Capital
Series A (2020): $4.2M featuring Cultivation Capital
Key Investors in Avail Pharma
Cultivation Capital
Cultivation Capital is a venture capital firm that invests in young companies with transformative ideas across various industries, including life sciences, software, agriculture, and geospatial technology. The firm provides capital resources and a vast network of partners to help startups navigate the challenges of hyper growth from Series Seed through Series B. With a focus on the Midwest, Cultivation Capital aims to support companies that have achieved measurable milestones and demonstrate potential for success. Their portfolio includes a diverse range of innovative companies that are poised to make significant impacts in their respective fields.
M25 Group
M25 Group is a London-based removals and storage company established in 2008, offering a range of services including residential and business moves, property clearance, and storage solutions. The company has adapted to various economic challenges and evolved to meet the diverse needs of its clients, providing a comprehensive service that emphasizes order and transparency. M25 Group caters to both private clients and businesses, ensuring flexibility and sustainable solutions in a rapidly changing market. Their operations integrate logistics with digital trends, creating a seamless experience for customers navigating the complexities of moving and storage.
Charmides Capital
Charmides Capital is a venture capital firm located in Indiana that specializes in providing seed and Series A stage funding for tech companies in the Midwest. The firm focuses on identifying business-to-business software as a service companies with high growth potential and co-invests with institutional investors. With a diverse team of partners, Charmides Capital aims to bring strategic value to a variety of early-stage startups. The firm embodies the Greek virtue of sophrosyne, emphasizing self-awareness and responsibility in its investment approach.
What's next for Avail Pharma?
The recent major strategic investment of $4.2M positions Avail Pharma for accelerated growth and enhanced service offerings. This infusion of capital, part of its overall $7.1M in backing, suggests a strategic pivot towards scaling its consulting services, potentially expanding its global reach, or investing in new technological capabilities to better serve the pharmaceutical and biotech industries. The company's progression through various funding stages, culminating in this significant Series A round, indicates a strong market validation and a clear path toward solidifying its leadership in specialized life sciences consulting. Future endeavors will likely focus on leveraging this enhanced financial capacity to deepen its expertise and broaden its client base, further cementing its role as a key strategic partner in drug development and market access.
See full Avail Pharma company page
